Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III

GlobeNewswire March 8, 2021

Ultragenyx to Present at Barclays Global Healthcare Conference

GlobeNewswire March 3, 2021

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire February 17, 2021

Ultragenyx Announces Approval of Dojolvi(TM) (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

GlobeNewswire February 17, 2021

Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

GlobeNewswire February 11, 2021

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update

GlobeNewswire February 4, 2021

Sizing Up the Sectors and Going for Growth: The 28th Annual Emerald Groundhog Day Investment Forum Goes Live on February 4th

Business Wire February 2, 2021

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease

GlobeNewswire January 21, 2021

28th Annual Emerald Groundhog Day Investment Forum Goes Virtual as Pandemic Casts a Long Shadow

Business Wire January 14, 2021

Ultragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx Territories

GlobeNewswire January 11, 2021

Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies

GlobeNewswire January 8, 2021

Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

GlobeNewswire January 5, 2021

Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

GlobeNewswire December 17, 2020

Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

GlobeNewswire December 17, 2020

Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease

GlobeNewswire December 9, 2020

GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome

GlobeNewswire December 5, 2020

Ultragenyx to Present at Upcoming Healthcare Conferences

GlobeNewswire November 24, 2020

Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases

GlobeNewswire November 9, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire November 5, 2020

Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 2, 2020